USFDA accepts Sun Pharma’s application for Tildrakizumab

25 May 2017 Evaluate

The US Food and Drug Administration (USFDA) has accepted Sun Pharmaceutical Industries’ Biologics License Application (BLA) for tildrakizumab. The USFDA filing acceptance follows the acceptance of the regulatory filing of tildrakizumab by the European Medicines Agency (EMA) in March 2017.

Tildrakizumab is an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate-to-severe plaque psoriasis. The BLA filing for tildrakizumab was submitted by Merck & Co., Inc., Kenilworth, NJ, USA.

Sun Pharmaceutical Industries is an Indian multinational pharmaceutical company that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) primarily in India and the United States. 


Sun Pharma Inds. Share Price

1589.30 -20.85 (-1.29%)
29-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1589.30
Dr. Reddys Lab 1208.45
Cipla 1320.35
Zydus Lifesciences 890.20
Lupin 2131.80
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×